EGFR 타깃 프로그램 | 바이오정보모아

Data Tier

ADC · Antibody · CGT를 FDA 승인, ORR·PASI·ACR·BCVA, 임상 등록 규모, Phase 3, 조회수 등 공개 데이터로 복합 점수화합니다. S–C 티어와 가점 요인은 규칙 기반(Data Tier)이며 LLM이 아닙니다.

EGFR 타깃

Data Tier

프로그램 (49)

Epidermal growth factor receptor (EGFRv, Epidermal growth factor receptor, Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL)

Pucotenlimab (Pucotenlimab)

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes)

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes)

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes)

CART-EGFR-IL13Ra2 Cells (CART-EGFR-IL13Ra2 Cells)

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes)

CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells (CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells)

autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells)

Nimotuzumab (Nimotuzumab)

Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes)

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes (Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes)

TGFβR-KO CAR-EGFR T Cells (TGFβR-KO CAR-EGFR T Cells)

Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors (Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors)

2nd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells))

EGFR/B7H3 CAR-T (EGFR/B7H3 CAR-T)

CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells (CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells)

durvalumab (Imfinzi, pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT)

atezolizumab (Tecentriq, Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab)

atezolizumab (Tecentriq, Carboplatin + Pemetrexed + Atezolizumab)

long spacer 2nd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells))

anti-CTLA-4/PD-1 expressing EGFR-CAR-T (anti-CTLA-4/PD-1 expressing EGFR-CAR-T)

Almonertinib/Furmonertinib/Osimertinib (third-generation EGFR TKIs, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib))

Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes)

EGFR inhibitors (panitumumab, panitumumab (EGFR inhibitors))

EGFRvIII CAR T cells (EGFRvIII CAR T cells)

CART-EGFR (CART-EGFR)

3rd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells))

Anti-VEGFR2 CAR CD8 plus PBL (Anti-VEGFR2 CAR CD8 plus PBL)

EGFR 타깃

Data Tier

프로그램 (49)

Epidermal growth factor receptor (EGFRv, Epidermal growth factor receptor, Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL)

Pucotenlimab (Pucotenlimab)

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes)

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes)

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes)

CART-EGFR-IL13Ra2 Cells (CART-EGFR-IL13Ra2 Cells)

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes)

CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells (CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells)

autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells)

Nimotuzumab (Nimotuzumab)

Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes)

Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed (Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed)

Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes (Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes)

TGFβR-KO CAR-EGFR T Cells (TGFβR-KO CAR-EGFR T Cells)

Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors (Vibecotecotamab combined with Putilimab for EGFR-positive refractory biliary malignant tumors)

2nd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells))

EGFR/B7H3 CAR-T (EGFR/B7H3 CAR-T)

CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells (CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells)

durvalumab (Imfinzi, pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT)

atezolizumab (Tecentriq, Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab)

atezolizumab (Tecentriq, Carboplatin + Pemetrexed + Atezolizumab)

long spacer 2nd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (long spacer 2nd generation T cells))

anti-CTLA-4/PD-1 expressing EGFR-CAR-T (anti-CTLA-4/PD-1 expressing EGFR-CAR-T)

Almonertinib/Furmonertinib/Osimertinib (third-generation EGFR TKIs, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib))

Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes)

EGFR inhibitors (panitumumab, panitumumab (EGFR inhibitors))

EGFRvIII CAR T cells (EGFRvIII CAR T cells)

CART-EGFR (CART-EGFR)

3rd generation T cells (Patient Derived CD171 specific CAR T cells expressing EGFRt, Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells))

Anti-VEGFR2 CAR CD8 plus PBL (Anti-VEGFR2 CAR CD8 plus PBL)

EGFR 타깃

Data Tier

프로그램 (49)

Epidermal growth factor receptor (EGFRv, Epidermal growth factor receptor, Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL)

Pucotenlimab (Pucotenlimab)

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem T-lymphocytes)

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes)

CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes)

CART-EGFR-IL13Ra2 Cells (CART-EGFR-IL13Ra2 Cells)

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes)

CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells (CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells)

autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells)

Nimotuzumab (Nimotuzumab)

Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes)